Glow Blend (Peptide)

Glow Peptide is a multi-peptide research blend that combines BPC-157, TB-500, and GHK-Cu into a single lyophilized (also referred to as lyophilized) vial for streamlined in vitro and in vivo investigation. Known interchangeably as Glow Blend and Glow Stack within the research community, this formulation brings together three peptides whose individual mechanisms of action target overlapping yet distinct pathways in tissue repair, extracellular matrix remodeling (also spelled remodeling), and cellular regeneration. ^(1,2,3)

The rationale behind the Glow Peptide formulation is rooted in the principle of synergistic peptide signaling (also spelled signaling). Rather than administering each peptide independently, researchers can study the combined downstream effects of a gastric pentadecapeptide (BPC-157), an actin-sequestering beta-thymosin (TB-500), and a copper-binding tripeptide (GHK-Cu) within a single experimental framework. Preclinical evidence suggests that the pathways modulated by these three peptides, including nitric oxide signaling, angiogenesis, collagen deposition, and regulation of anti-inflammatory cytokines, converge to achieve tissue restoration outcomes that may exceed the sum of their individual contributions. ^(1,2,3)

Healius Peptides offers Glow Peptide in two variants, each designed for a different research application. The 50mg vial contains 5mg BPC-157, 10mg TB-500, and 35mg GHK-Cu. The 70mg vial contains 10mg BPC-157, 10mg TB-500, and 50mg GHK-Cu. Both variants are manufactured under strict quality controls, 3rd-party tested, and verified to >99% purity, with full Certificates of Analysis available on the Healius Lab Testing.

Glow Peptide contains three active peptide components; each selected for its well-characterized (also referred to as characterized) role in regenerative research. Understanding the individual profile of each ingredient is essential for researchers designing protocols around the Glow Stack formulation.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide with a molecular weight of approximately 1,419 Da and the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Within the Glow Peptide formulation, BPC-157’s primary contribution is its angiogenic activity, which promotes the formation of new blood vessels and improves microcirculation at tissue sites. In preclinical skin and wound models, this translates to accelerated nutrient delivery to dermal tissue, faster wound closure, and improved vascularisation of healing tissue. BPC-157 also modulates the nitric oxide system and upregulates growth factor expression, with additional activity documented in tendon, ligament, muscle, and gastrointestinal mucosal repair models. ^(1,4)

TB-500 (Thymosin Beta-4 Fragment) is a 43-amino-acid peptide central to actin polymerization (also referred to as polymerization) and cytoskeletal organization (also referred to as organization). In the context of the Glow Blend, TB-500’s most relevant activity is its ability to drive cell migration to wound sites and reduce scar tissue formation, both of which are critical for skin repair outcomes. Preclinical dermatological studies show that TB-500 promotes hair-follicle stem cell migration, suppresses pro-inflammatory cytokine production at wound margins, and reduces fibrosis, all of which contribute to cleaner, faster dermal healing with less scarring. TB-500 has also demonstrated favorable (also spelled favorable) outcomes in cardiac tissue repair and broader musculoskeletal recovery models. ^(2,5)

GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper Complex) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. GHK-Cu concentrations decline significantly with age, from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60. Research has identified GHK-Cu as a potent modulator of gene expression, with published studies showing it can reset the expression of over 4,000 human genes toward a healthier profile. Its primary research applications include stimulating collagen and elastin synthesis, upregulating antioxidant enzyme activity, and remodeling the extracellular matrix. ^(3,6)

Glow Peptide’s mechanism of action is best understood as a convergence of three complementary biological pathways. Each component activates distinct molecular targets, yet the downstream effects overlap, potentially amplifying the overall regenerative response.

The BPC-157 component primarily modulates the nitric oxide (NO) system and the FAK-paxillin pathway. Animal model data show that BPC-157 promotes endothelial cell proliferation and new blood vessel formation at injury sites, accelerating the delivery of nutrients and growth factors to damaged tissue. BPC-157 has also been shown to interact with the dopaminergic, serotonergic, and GABAergic systems, and to counteract the effects of several pharmacological agents on organ function in preclinical models. ^(1,4)

TB-500 contributes to the blend by regulating actin dynamics. By sequestering G-actin monomers and promoting their controlled polymerization into F-actin filaments, TB-500 facilitates the cytoskeletal reorganization required for cell migration to wound sites. This mechanism is critical for both the inflammatory and proliferative phases of tissue repair. In preclinical dermatological models, TB-500 has also been shown to promote hair-follicle stem-cell migration, suppress pro-inflammatory cytokine production, and reduce oxidative stress markers. ^(2,5)

GHK-Cu provides the matrix-level regenerative component. As a copper-delivery peptide, GHK-Cu activates metalloproteinases involved in extracellular matrix turnover while simultaneously stimulating the synthesis of new collagen types I, III, and V, as well as elastin, decorin, and glycosaminoglycans. GHK-Cu has been shown to upregulate genes associated with antioxidant defense (superoxide dismutase, glutathione reductase) and to downregulate genes linked to inflammation and tissue destruction. Research also indicates that GHK-Cu stimulates dermal fibroblast proliferation, nerve growth factor synthesis, and integrin expression, supporting the structural and signaling infrastructure required for full-depth tissue regeneration. ^(3,6)

When combined in the Glow Peptide formulation, these three mechanisms create a multi-layered research model: BPC-157 drives vascularisation and systemic repair signaling, TB-500 enables cellular migration and cytoskeletal readiness, and GHK-Cu rebuilds the structural matrix and resets gene expression toward regenerative activity. Researchers studying tissue repair, wound healing, skin rejuvenation, and aging (also spelled aging) reversal models have increasingly adopted multi-peptide protocols such as the Glow Stack to examine these convergent pathways in controlled experimental settings.

The research benefits of Glow Peptide stem from the combined investigational profiles of its three components. Hundreds of peer-reviewed studies across the BPC-157, TB-500, and GHK-Cu literature support the following areas of interest for the Glow Blend formulation.

In tissue repair and wound healing research, BPC-157 has demonstrated accelerated recovery in preclinical models involving tendons, ligaments, muscles, and bone fractures. ⁽¹⁾ TB-500 has shown the ability to promote cell migration into wound sites, reduce scar tissue formation, and improve functional recovery outcomes. ⁽²⁾ GHK-Cu has been reported to stimulate collagen and elastin synthesis, activate dermal fibroblasts, and promote nerve regeneration at injury sites. ⁽³⁾

In skin and dermatological research, GHK-Cu stands as the most directly relevant component. Ex vivo skin models and preclinical studies report increased skin thickness, improved elasticity, reduced fine lines, and enhanced color (also spelled color) uniformity following GHK-Cu treatment. ⁽⁶⁾ BPC-157 contributes through its angiogenic properties, improving blood supply to dermal tissue, while TB-500 supports hair follicle stem cell activation and the reduction of inflammatory skin markers. ^(2,5)

In anti-inflammatory research, all three peptides demonstrate complementary activity. BPC-157 modulates inflammatory cytokine cascades and has demonstrated gastroprotective effects in models of NSAID-induced damage. ⁽⁴⁾ TB-500 suppresses NF-kB-mediated inflammation and reduces oxidative stress markers. ⁽⁵⁾ GHK-Cu downregulates genes associated with chronic inflammation, including those encoding IL-6 and TNF-alpha receptors. ⁽⁶⁾

In anti-aging and longevity research, GHK-Cu’s ability to reset over 4,000 human genes toward youthful expression patterns has attracted significant attention in the gerontological research community. ⁽³⁾ Combined with BPC-157’s systemic protective effects and TB-500’s regenerative cell migration properties, the Glow Peptide blend gives researchers a three-axis model for studying age-related tissue decline and potential intervention strategies.

Researchers seeking complementary antioxidant support in their protocols may also consider L-Glutathione, which operates through the glutathione pathway to reduce oxidative damage at the cellular level.

Glow Peptide dosage in research settings varies depending on the experimental model, the specific variant selected (50mg or 70mg), and the target outcomes under investigation. The peer-reviewed literature on each component provides dosing frameworks that inform the design of the Glow Blend protocol.

BPC-157 has been studied at doses ranging from 1 to 10 mcg/kg in preclinical models, administered via subcutaneous, intraperitoneal, or intragastric routes depending on the target tissue. ⁽¹⁾ TB-500 research protocols typically utilize (also referred to as utilize) doses in the range of 2 to 6 mg per administration in larger animal models, with frequency varying from daily to twice weekly depending on the study design. ⁽²⁾ GHK-Cu has been investigated at concentrations ranging from 0.1 to 10 mcg/mL in cell culture systems, and at systemic doses from 0.5 to 5 mg/kg in animal models. ⁽³⁾

The Healius Glow Peptide Dosage Calculator provides a tool for researchers to calculate reconstitution volumes and individual component concentrations per injection volume for both the 50mg and 70mg variants.

Multi-peptide blend protocols in the literature generally follow a loading phase of higher-frequency administration (typically daily for 4 to 6 weeks), followed by a maintenance phase at reduced frequency (2 to 3 times per week). Optimal dosing for the combined Glow Stack formulation has not been established in human clinical trials, and all dosage information is extrapolated from preclinical data for individual components. Independent ethical review and institutional oversight are essential before initiating any in vivo research protocol.

Healius Peptides offers Glow Peptide in two distinct formulations to accommodate different research requirements. The primary difference between the Glow 50 and Glow 70 variants lies in the total peptide content per vial and the ratio of each component.

The Glow 50 variant contains a total of 50mg of peptide: 5mg BPC-157, 10mg TB-500, and 35mg GHK-Cu. This formulation provides a GHK-Cu-dominant ratio (70% of total content), making it particularly suited for research protocols where extracellular matrix remodeling, collagen synthesis, and skin rejuvenation endpoints are the primary focus. The lower BPC-157 content (10% of the total) is sufficient to support vascularisation research without dominating the blend’s overall activity profile.

The Glow 70 variant contains 70mg total peptide: 10mg BPC-157, 10mg TB-500, and 50mg GHK-Cu. This formulation doubles the BPC-157 content compared to the 50mg variant, providing a more balanced repair-to-regeneration ratio. The increased BPC-157 dose supports research protocols that study tissue repair, gastroprotection, or systemic protective effects alongside GHK-Cu’s matrix-level activity. The TB-500 content remains consistent across both variants at 10mg, ensuring equivalent cell migration and anti-inflammatory support regardless of the variant selected.

Both variants maintain the same GHK-Cu-dominant architecture, reflecting the published research’s emphasis on copper-peptide activity in regenerative and dermatological models. Researchers studying primarily skin-related endpoints may find the 50mg variant cost-effective for long-duration protocols. In comparison, those investigating broader tissue repair models may prefer the 70mg variant’s enhanced BPC-157 content.

1. Seiwerth S, et al. “BPC 157’s effect on healing.” Journal of Physiology-Paris, 1999; 93(6): 441-456. Comprehensive review of BPC-157 mechanisms, including gastric pentadecapeptide activity, nitric oxide modulation, angiogenesis promotion, and tissue repair across tendon, ligament, muscle, and bone preclinical models.

2. Goldstein AL, et al. “Thymosin beta-4: a multi-functional regenerative peptide.” Expert Opinion on Biological Therapy, 2012; 12(Suppl 1): S37-S51. Review of TB-500/Thymosin Beta-4 mechanisms, including actin regulation, cell migration, wound healing, hair follicle stem cell activation, and anti-inflammatory properties.

3. Pickart L, et al. “The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging.” International Journal of Molecular Sciences, 2012; 13(9): 11699-11720. Key study on GHK-Cu gene expression modulation (4,000+ genes), collagen synthesis stimulation, antioxidant enzyme upregulation, and age-related decline in plasma GHK-Cu concentrations.

4. Sikiric P, et al. “Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.” Current Pharmaceutical Design, 2011; 17(16): 1612-1632. Detailed examination of BPC-157 gastroprotective effects, cytoprotective mechanisms, interaction with the NO system, and FAK-paxillin pathway modulation in multiple organ damage models.

5. Sosne G et al. “Thymosin beta 4 promotes dermal healing.” Annals of the New York Academy of Sciences, 2010; 1194: 112-117. Study demonstrating TB-500 activity in dermal wound-healing models, including promotion of cell migration, anti-inflammatory effects, and modulation of the NF-kB pathway.

6. Pickart L, Margolina A. “Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data.” International Journal of Molecular Sciences, 2018; 19(7): 1987. Updated analysis of GHK-Cu gene expression data showing upregulation of collagen, elastin, decorin, and glycosaminoglycan synthesis genes, plus downregulation of inflammatory and tissue-destructive gene networks.

7. Kannengiesser K et al. “Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.” Inflammatory Bowel Diseases, 2008; 14(3): 324-331. Preclinical evidence for KPV anti-inflammatory activity, including NF-kB modulation, pro-inflammatory cytokine suppression, and mucosal immune support.

8. Vasireddi N, et al. “Emerging Use of BPC-157 in Orthopedic Sports Medicine: A Systematic Review.” HSS Journal, 2025. Systematic review covering BPC-157 mechanism of action, musculoskeletal effects, metabolism, safety profile, and regulatory/WADA status.

9. Philp D et al. “Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice.” Wound Repair and Regeneration, 2003; 11(1): 19-24. Preclinical evidence for TB-500 wound healing efficacy in impaired healing models.

This product is intended for research use only (RUO). It is not intended for human or veterinary diagnostic, therapeutic, or clinical use. Glow Peptide is not a drug, food, cosmetic, or dietary supplement and may not be misbranded, misused, or mislabeled as such. All information provided in this product description is for educational and informational purposes only and is based on published peer-reviewed research. Healius Peptides makes no claims regarding the therapeutic efficacy of this product in humans. Researchers are responsible for ensuring compliance with all applicable local, state, federal, and international regulations governing the purchase, handling, and use of research peptides.